Usa Britain state Maryland South Africa Mexico covid-19 vaccine novavax Usa Britain state Maryland South Africa Mexico

Novavax COVID vaccine shows 90.4% efficacy against infection

Reading now: 335
www.cidrap.umn.edu

A phase 3 trial yesterday in the New England Journal of Medicine (NEJM) finds that the Novavax COVID-19 vaccine is 90.4% effective against infection and 100% effective against moderate to severe illness, bringing yet another vaccine one step closer to approval.Novavax is a new adjuvanted, recombinant spike protein nanoparticle vaccine that has proven effective against COVID-19 infection in the United Kingdom and South Africa.

This was the first such trial in North America.The study, led by Novavax researchers in Gaithersburg, Maryland, involved 29,949 adults who received the Novavax vaccine at 113 sites in the United States and 6 in Mexico from Dec 27, 2020, to Feb 18, 2021, before the emergence of the highly transmissible Delta (B1617.2)

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA